0359 FarGen-PGx: Pharmacogenomics within the Faroese Populatio

With the project “FarGen-PGx: Pharmacogenomics within the Faroese Population“ we aim to describethe relationship between genes and medication respond (PGx) in the Faroese population by incorporate genetic data from the FarGen-infrastructure with pharmaceutical records. It is well known that individuals vary considerably in their response to medication. Some patients show a substantial therapeutic response to a given drug, while others may not and may even experience adverse side-effects. In
addition, certain patients may require considerably higher or lower doses of a medication to achieve maximum benefit. It is recognized that parts of the individual variation in therapeutic response is inherited and genetic variants are estimated to affect between 20–95% of the response variability.
Therapeutic response is therefore potentially predictable by using PGx markers. This project is a comprehensive approach to bring forward PGx tests into routine use in the Faroese Health care system.

Pharmacogenomics (PGx) lýsir sambandið millum ílegur og heilivágsvirkna. Ætlanin við hesi verkætlan er, at lýsa hetta sambandið hjá føroyingum við at sameina ílegudátur frá FarGen- dátugrunnunum við heilivágsdátur. Heilivágur kann virka ymiskt hjá ymiskum fólkum. Hjá summum virkar heilivágurin sum ætlað, meðan sami heilivágur hjá summum als ikki virkar, og hjá uppaftur øðrum síggjast nógv hjáárin. Vit vita, at orsøkirnar til hendan munin lutvíst finnast í okkara ílegum. Staðfest er, at heilivágsvirknaður lutvíst er arvaligur, og mett verður, at íleguvariantar ávirka heilivágsvirkna við 20-95 %. Við at kanna hesar íleguvariantarnar ber til at meta um, hvussu ávísur heilivágur virkar hjá tí einstaka, áðrenn hann verður givin. Henda verkætlanin kann tí gerast eitt týdningarmikið stig í tilgongdini at nýta ílegukanningar í samband við heilivágsviðgerð í føroyska heilsuverkinum.